nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftizoxime—Induration—Imiquimod—skin cancer	0.0437	0.0437	CcSEcCtD
Ceftizoxime—Induration—Bleomycin—skin cancer	0.0311	0.0311	CcSEcCtD
Ceftizoxime—Nephropathy toxic—Bleomycin—skin cancer	0.0242	0.0242	CcSEcCtD
Ceftizoxime—Tenderness—Imiquimod—skin cancer	0.0224	0.0224	CcSEcCtD
Ceftizoxime—Vaginal inflammation—Imiquimod—skin cancer	0.0196	0.0196	CcSEcCtD
Ceftizoxime—Vaginal infection—Imiquimod—skin cancer	0.0185	0.0185	CcSEcCtD
Ceftizoxime—Tenderness—Bleomycin—skin cancer	0.0159	0.0159	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.015	0.015	CcSEcCtD
Ceftizoxime—Eosinophilia—Vemurafenib—skin cancer	0.0142	0.0142	CcSEcCtD
Ceftizoxime—Numbness—Fluorouracil—skin cancer	0.013	0.013	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.0127	0.0127	CcSEcCtD
Ceftizoxime—Sensory loss—Fluorouracil—skin cancer	0.0125	0.0125	CcSEcCtD
Ceftizoxime—Tenderness—Fluorouracil—skin cancer	0.0124	0.0124	CcSEcCtD
Ceftizoxime—Aplastic anaemia—Dactinomycin—skin cancer	0.0122	0.0122	CcSEcCtD
Ceftizoxime—Cellulitis—Fluorouracil—skin cancer	0.0119	0.0119	CcSEcCtD
Ceftizoxime—Vaginal inflammation—Temozolomide—skin cancer	0.0117	0.0117	CcSEcCtD
Ceftizoxime—Phlebitis—Bleomycin—skin cancer	0.0117	0.0117	CcSEcCtD
Ceftizoxime—Pancytopenia—Imiquimod—skin cancer	0.0117	0.0117	CcSEcCtD
Ceftizoxime—Pain—Vismodegib—skin cancer	0.0113	0.0113	CcSEcCtD
Ceftizoxime—Vaginal infection—Temozolomide—skin cancer	0.0111	0.0111	CcSEcCtD
Ceftizoxime—Aplastic anaemia—Temozolomide—skin cancer	0.011	0.011	CcSEcCtD
Ceftizoxime—Phlebitis—Dactinomycin—skin cancer	0.0109	0.0109	CcSEcCtD
Ceftizoxime—Erythema multiforme—Vemurafenib—skin cancer	0.0109	0.0109	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.0108	0.0108	CcSEcCtD
Ceftizoxime—Haemoglobin—Imiquimod—skin cancer	0.00987	0.00987	CcSEcCtD
Ceftizoxime—Haemorrhage—Imiquimod—skin cancer	0.00982	0.00982	CcSEcCtD
Ceftizoxime—Pruritus—Vismodegib—skin cancer	0.00937	0.00937	CcSEcCtD
Ceftizoxime—Erythema multiforme—Imiquimod—skin cancer	0.00929	0.00929	CcSEcCtD
Ceftizoxime—Diarrhoea—Vismodegib—skin cancer	0.00906	0.00906	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00847	0.00847	CcSEcCtD
Ceftizoxime—Vomiting—Vismodegib—skin cancer	0.00842	0.00842	CcSEcCtD
Ceftizoxime—Rash—Vismodegib—skin cancer	0.00835	0.00835	CcSEcCtD
Ceftizoxime—Dermatitis—Vismodegib—skin cancer	0.00834	0.00834	CcSEcCtD
Ceftizoxime—Pancytopenia—Bleomycin—skin cancer	0.00828	0.00828	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Vemurafenib—skin cancer	0.00818	0.00818	CcSEcCtD
Ceftizoxime—Nausea—Vismodegib—skin cancer	0.00787	0.00787	CcSEcCtD
Ceftizoxime—Pancytopenia—Dactinomycin—skin cancer	0.00772	0.00772	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00766	0.00766	CcSEcCtD
Ceftizoxime—Neutropenia—Dactinomycin—skin cancer	0.0076	0.0076	CcSEcCtD
Ceftizoxime—Convulsion—Imiquimod—skin cancer	0.00741	0.00741	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00719	0.00719	CcSEcCtD
Ceftizoxime—Haemoglobin—Bleomycin—skin cancer	0.00701	0.00701	CcSEcCtD
Ceftizoxime—Pancytopenia—Temozolomide—skin cancer	0.00698	0.00698	CcSEcCtD
Ceftizoxime—Haemorrhage—Bleomycin—skin cancer	0.00698	0.00698	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Bleomycin—skin cancer	0.00694	0.00694	CcSEcCtD
Ceftizoxime—Neutropenia—Temozolomide—skin cancer	0.00688	0.00688	CcSEcCtD
Ceftizoxime—Agranulocytosis—Dactinomycin—skin cancer	0.00677	0.00677	CcSEcCtD
Ceftizoxime—Eosinophilia—Fluorouracil—skin cancer	0.00671	0.00671	CcSEcCtD
Ceftizoxime—Phlebitis—Docetaxel—skin cancer	0.00657	0.00657	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.0065	0.0065	CcSEcCtD
Ceftizoxime—Body temperature increased—Vemurafenib—skin cancer	0.00647	0.00647	CcSEcCtD
Ceftizoxime—Pancytopenia—Fluorouracil—skin cancer	0.00644	0.00644	CcSEcCtD
Ceftizoxime—Paraesthesia—Imiquimod—skin cancer	0.00627	0.00627	CcSEcCtD
Ceftizoxime—Erythema multiforme—Dactinomycin—skin cancer	0.00615	0.00615	CcSEcCtD
Ceftizoxime—Hypersensitivity—Vemurafenib—skin cancer	0.00603	0.00603	CcSEcCtD
Ceftizoxime—Pain—Imiquimod—skin cancer	0.00597	0.00597	CcSEcCtD
Ceftizoxime—Haemoglobin—Temozolomide—skin cancer	0.00592	0.00592	CcSEcCtD
Ceftizoxime—Haemorrhage—Temozolomide—skin cancer	0.00589	0.00589	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Temozolomide—skin cancer	0.00586	0.00586	CcSEcCtD
Ceftizoxime—Pruritus—Vemurafenib—skin cancer	0.00579	0.00579	CcSEcCtD
Ceftizoxime—Agranulocytosis—Fluorouracil—skin cancer	0.00564	0.00564	CcSEcCtD
Ceftizoxime—Anaemia—Bleomycin—skin cancer	0.00562	0.00562	CcSEcCtD
Ceftizoxime—Diarrhoea—Vemurafenib—skin cancer	0.0056	0.0056	CcSEcCtD
Ceftizoxime—Erythema multiforme—Temozolomide—skin cancer	0.00557	0.00557	CcSEcCtD
Ceftizoxime—Body temperature increased—Imiquimod—skin cancer	0.00552	0.00552	CcSEcCtD
Ceftizoxime—Haemoglobin—Fluorouracil—skin cancer	0.00545	0.00545	CcSEcCtD
Ceftizoxime—Leukopenia—Bleomycin—skin cancer	0.00544	0.00544	CcSEcCtD
Ceftizoxime—Haemorrhage—Fluorouracil—skin cancer	0.00542	0.00542	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Fluorouracil—skin cancer	0.0054	0.0054	CcSEcCtD
Ceftizoxime—Anaemia—Dactinomycin—skin cancer	0.00524	0.00524	CcSEcCtD
Ceftizoxime—Vomiting—Vemurafenib—skin cancer	0.0052	0.0052	CcSEcCtD
Ceftizoxime—Rash—Vemurafenib—skin cancer	0.00516	0.00516	CcSEcCtD
Ceftizoxime—Dermatitis—Vemurafenib—skin cancer	0.00516	0.00516	CcSEcCtD
Ceftizoxime—Hypersensitivity—Imiquimod—skin cancer	0.00514	0.00514	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.0051	0.0051	CcSEcCtD
Ceftizoxime—Leukopenia—Dactinomycin—skin cancer	0.00507	0.00507	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Bleomycin—skin cancer	0.00496	0.00496	CcSEcCtD
Ceftizoxime—Pruritus—Imiquimod—skin cancer	0.00494	0.00494	CcSEcCtD
Ceftizoxime—Nausea—Vemurafenib—skin cancer	0.00486	0.00486	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Bleomycin—skin cancer	0.00485	0.00485	CcSEcCtD
Ceftizoxime—Diarrhoea—Imiquimod—skin cancer	0.00478	0.00478	CcSEcCtD
Ceftizoxime—Anaemia—Temozolomide—skin cancer	0.00474	0.00474	CcSEcCtD
Ceftizoxime—Pancytopenia—Docetaxel—skin cancer	0.00464	0.00464	CcSEcCtD
Ceftizoxime—Leukopenia—Temozolomide—skin cancer	0.00459	0.00459	CcSEcCtD
Ceftizoxime—Neutropenia—Docetaxel—skin cancer	0.00457	0.00457	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Dactinomycin—skin cancer	0.00453	0.00453	CcSEcCtD
Ceftizoxime—Paraesthesia—Bleomycin—skin cancer	0.00445	0.00445	CcSEcCtD
Ceftizoxime—Convulsion—Temozolomide—skin cancer	0.00444	0.00444	CcSEcCtD
Ceftizoxime—Vomiting—Imiquimod—skin cancer	0.00444	0.00444	CcSEcCtD
Ceftizoxime—Rash—Imiquimod—skin cancer	0.0044	0.0044	CcSEcCtD
Ceftizoxime—Dermatitis—Imiquimod—skin cancer	0.0044	0.0044	CcSEcCtD
Ceftizoxime—Anaemia—Fluorouracil—skin cancer	0.00436	0.00436	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00432	0.00432	CcSEcCtD
Ceftizoxime—Pain—Bleomycin—skin cancer	0.00424	0.00424	CcSEcCtD
Ceftizoxime—Leukopenia—Fluorouracil—skin cancer	0.00423	0.00423	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Temozolomide—skin cancer	0.00418	0.00418	CcSEcCtD
Ceftizoxime—Nausea—Imiquimod—skin cancer	0.00415	0.00415	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Temozolomide—skin cancer	0.0041	0.0041	CcSEcCtD
Ceftizoxime—Convulsion—Fluorouracil—skin cancer	0.00409	0.00409	CcSEcCtD
Ceftizoxime—Agranulocytosis—Docetaxel—skin cancer	0.00407	0.00407	CcSEcCtD
Ceftizoxime—Pain—Dactinomycin—skin cancer	0.00395	0.00395	CcSEcCtD
Ceftizoxime—Haemoglobin—Docetaxel—skin cancer	0.00393	0.00393	CcSEcCtD
Ceftizoxime—Body temperature increased—Bleomycin—skin cancer	0.00392	0.00392	CcSEcCtD
Ceftizoxime—Haemorrhage—Docetaxel—skin cancer	0.00391	0.00391	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Docetaxel—skin cancer	0.0039	0.0039	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Fluorouracil—skin cancer	0.00385	0.00385	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Fluorouracil—skin cancer	0.00377	0.00377	CcSEcCtD
Ceftizoxime—Paraesthesia—Temozolomide—skin cancer	0.00376	0.00376	CcSEcCtD
Ceftizoxime—Erythema multiforme—Docetaxel—skin cancer	0.0037	0.0037	CcSEcCtD
Ceftizoxime—Body temperature increased—Dactinomycin—skin cancer	0.00366	0.00366	CcSEcCtD
Ceftizoxime—Hypersensitivity—Bleomycin—skin cancer	0.00365	0.00365	CcSEcCtD
Ceftizoxime—Pain—Temozolomide—skin cancer	0.00358	0.00358	CcSEcCtD
Ceftizoxime—Pruritus—Bleomycin—skin cancer	0.00351	0.00351	CcSEcCtD
Ceftizoxime—Paraesthesia—Fluorouracil—skin cancer	0.00346	0.00346	CcSEcCtD
Ceftizoxime—Hypersensitivity—Dactinomycin—skin cancer	0.00341	0.00341	CcSEcCtD
Ceftizoxime—Body temperature increased—Temozolomide—skin cancer	0.00331	0.00331	CcSEcCtD
Ceftizoxime—Pain—Fluorouracil—skin cancer	0.0033	0.0033	CcSEcCtD
Ceftizoxime—Diarrhoea—Dactinomycin—skin cancer	0.00316	0.00316	CcSEcCtD
Ceftizoxime—Vomiting—Bleomycin—skin cancer	0.00315	0.00315	CcSEcCtD
Ceftizoxime—Anaemia—Docetaxel—skin cancer	0.00315	0.00315	CcSEcCtD
Ceftizoxime—Rash—Bleomycin—skin cancer	0.00313	0.00313	CcSEcCtD
Ceftizoxime—Dermatitis—Bleomycin—skin cancer	0.00312	0.00312	CcSEcCtD
Ceftizoxime—Hypersensitivity—Temozolomide—skin cancer	0.00308	0.00308	CcSEcCtD
Ceftizoxime—Leukopenia—Docetaxel—skin cancer	0.00305	0.00305	CcSEcCtD
Ceftizoxime—Body temperature increased—Fluorouracil—skin cancer	0.00305	0.00305	CcSEcCtD
Ceftizoxime—Pruritus—Temozolomide—skin cancer	0.00296	0.00296	CcSEcCtD
Ceftizoxime—Convulsion—Docetaxel—skin cancer	0.00295	0.00295	CcSEcCtD
Ceftizoxime—Nausea—Bleomycin—skin cancer	0.00295	0.00295	CcSEcCtD
Ceftizoxime—Vomiting—Dactinomycin—skin cancer	0.00294	0.00294	CcSEcCtD
Ceftizoxime—Rash—Dactinomycin—skin cancer	0.00292	0.00292	CcSEcCtD
Ceftizoxime—Diarrhoea—Temozolomide—skin cancer	0.00286	0.00286	CcSEcCtD
Ceftizoxime—Hypersensitivity—Fluorouracil—skin cancer	0.00284	0.00284	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Docetaxel—skin cancer	0.00278	0.00278	CcSEcCtD
Ceftizoxime—Nausea—Dactinomycin—skin cancer	0.00275	0.00275	CcSEcCtD
Ceftizoxime—Pruritus—Fluorouracil—skin cancer	0.00273	0.00273	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Docetaxel—skin cancer	0.00272	0.00272	CcSEcCtD
Ceftizoxime—Vomiting—Temozolomide—skin cancer	0.00266	0.00266	CcSEcCtD
Ceftizoxime—Rash—Temozolomide—skin cancer	0.00264	0.00264	CcSEcCtD
Ceftizoxime—Diarrhoea—Fluorouracil—skin cancer	0.00264	0.00264	CcSEcCtD
Ceftizoxime—Dermatitis—Temozolomide—skin cancer	0.00263	0.00263	CcSEcCtD
Ceftizoxime—Paraesthesia—Docetaxel—skin cancer	0.0025	0.0025	CcSEcCtD
Ceftizoxime—Nausea—Temozolomide—skin cancer	0.00248	0.00248	CcSEcCtD
Ceftizoxime—Vomiting—Fluorouracil—skin cancer	0.00245	0.00245	CcSEcCtD
Ceftizoxime—Rash—Fluorouracil—skin cancer	0.00243	0.00243	CcSEcCtD
Ceftizoxime—Dermatitis—Fluorouracil—skin cancer	0.00243	0.00243	CcSEcCtD
Ceftizoxime—Pain—Docetaxel—skin cancer	0.00238	0.00238	CcSEcCtD
Ceftizoxime—Nausea—Fluorouracil—skin cancer	0.00229	0.00229	CcSEcCtD
Ceftizoxime—Body temperature increased—Docetaxel—skin cancer	0.0022	0.0022	CcSEcCtD
Ceftizoxime—Hypersensitivity—Docetaxel—skin cancer	0.00205	0.00205	CcSEcCtD
Ceftizoxime—Pruritus—Docetaxel—skin cancer	0.00197	0.00197	CcSEcCtD
Ceftizoxime—Diarrhoea—Docetaxel—skin cancer	0.0019	0.0019	CcSEcCtD
Ceftizoxime—Vomiting—Docetaxel—skin cancer	0.00177	0.00177	CcSEcCtD
Ceftizoxime—Rash—Docetaxel—skin cancer	0.00175	0.00175	CcSEcCtD
Ceftizoxime—Dermatitis—Docetaxel—skin cancer	0.00175	0.00175	CcSEcCtD
Ceftizoxime—Nausea—Docetaxel—skin cancer	0.00165	0.00165	CcSEcCtD
